Ask AI
ProCE Banner Activity

Experts Answer HCP Questions on CLL Therapy

Clinical Thought

In this commentary, expert faculty discuss questions on the management of patients with CLL from HCPs working within the VA hospital system who attended live educational webinars, including treatment selection and sequencing, managing “double refractory” CLL, and emerging therapies.

Released: October 27, 2025

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Lilly and Merck Sharp & Dohme LLC.

Lilly

Merck Sharp & Dohme, LLC

Disclosure

Primary Author

Solomon A. Graf, MD: researcher (paid to institution): AstraZeneca/Acerta Pharma, BeiGene, Genentech, Janssen.

Sameer A. Parikh, MBBS: researcher (paid to institution): AstraZeneca, Genentech, Janssen, Merck; consultant/advisor (paid to institution): AbbVie, AstraZeneca, BeiGene, Genentech, Janssen, Kite, Merck, MingSight, NovalGen, Pharmacyclics, Sobi.